179174-79-9

Usage

Uses

Used in Pharmaceutical Industry:
(Z)-4-acetoxy-3-(4-(Methylsulfonyl) phenyl)-2-phenylbut-2-enoic acid is utilized as an anti-inflammatory agent for the treatment of various conditions characterized by pain and inflammation. Its application is particularly beneficial in managing arthritis, menstrual cramps, and other similar afflictions. The selective inhibition of COX-2 makes it a preferred choice for reducing inflammation with fewer gastrointestinal side effects compared to traditional NSAIDs.
However, due to the potential for side effects and interactions with other medications, the use of (Z)-4-acetoxy-3-(4-(Methylsulfonyl) phenyl)-2-phenylbut-2-enoic acid should be carefully monitored and administered under the guidance of a healthcare professional. This ensures that the therapeutic benefits are maximized while minimizing the risk of adverse reactions.

Upstream product

• 179174-77-7 (2Z)-4-hydroxy-2-[4-(methylsulfonyl)phenyl]-3-phenylbut-2-enyl acetate 
• 10049-21-5 sodium dihydrogenphosphate 
• 513-35-9 2-methyl-but-2-ene 
• 87413-09-0 Dess-Martin periodane 
• 754242-11-0 (Z)-4-Acetoxy-3-(4-methylsulfanyl-phenyl)-2-phenyl-but-2-enoic acid 

Downstream Products

• 754242-04-1 6-bromohexyl (2Z)-4-(acetyloxy)-3-[4-(methylsulfonyl)phenyl]-2-phenylbut-2-enoate 
• 754242-12-1 (Z)-4-Acetoxy-3-(4-methanesulfonyl-phenyl)-2-phenyl-but-2-enoic acid 6-hydroxy-hexyl ester 

Relevant academic research and scientific papers

Synthesis of a NO-releasing prodrug of rofecoxib

A newly developed synthesis of a NO-releasing prodrug of rofecoxib is described. The highly productive process consists of five chemical steps and produces prodrug 1 in an overall 64% yield from commercially available 3-phenyl-2-propyn-1-ol (4). The synth

NITRIC OXIDE RELEASING PRODRUGS OF DIARYL-2-(5H)-FURANONES AS CYCLOOXYGENASE-2 INHIBITORS

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. Formula (I). The invention also encompasses certain pharmaceutical compositions and methods for treating cyclooxygenease-2 mediated diseases comprising the use of compounds of Formula I. The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while also reducing the risk of thrombotic cardiovascular events.

Process for making nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors

The invention encompasses a novel process for making compounds of Formula I which are prodrugs of cyclooxygenase-2 selective inhibitors that convert in vivo to diaryl-2-(5H)-furanones and also liberate nitric oxide in vivo. As such, the compounds made by

Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula I, which are nitric oxide-releasing prodrugs of diaryl-2-(5H) furanones useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions

Stilbene derivatives useful as cyclooxygenase-2 inhibitors

The invention encompasses novel compounds of Formula Iuseful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceuticalcompositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula I.